Shares
Stock
Stockbrokers
hit
have
had
has
by
both
boost,
become
better
believed
been
biggest
brought
bankruptcy
but
MS
Monday
Monday,
drug
drug.
death
deal
determine
disease
dosing
down
suspension
suspended
suspected
sales
said
sclerosis
share
shares
shed
system
statement.
stock
since,
set
in
involved
investigators
increased
increasing
inquiry
into
its
itself
it."
Elan
Elan,
Elan's
Exchange
Exchange,
an
and
analysts
as
after
action
accounts
alone.
also
almost
approved
availability."
at
agreement,
Biogen
Idec
Idec's
Idec,
Ireland-based
Irish
Ian
plunged
patient's
patients
partner
progressive
product
product.
provide
prompting
price
possible
pharmaceutical
pence
pull
on
once
of
or
out
outcome
opportunity
over
the
they
these
there's
to
took
taking
tipped
treatment.
trials
two
firm
firms
finished
from
for
four-fold
future
faced
fell
new
nervous
no
multiple
multifocal
mark
Tysabri
Tysabri-treated
Tysabri,"
The
US
US.
UK
On
New
November
York
Yamanouchi
lost
leukoencephalopathy
leading
level
last
likely
licensing
70%
while
which
was
widely
will
with
world's
work
would
43%.
central
case
cases
cash
condition
condition.
consult
companies
company
competition
commercial
cited
clinical
close
closed
use
used
understand
Avonex
Avonex,
Avonex.
An
Analysts
Alzheimer's
existing
experts
experimental
expected
exchange,
either
evaluate
evaluations
end
reports
re-initiation
receive
rebuilding
reserves.
rare
raise
risk
rivals
-
(PML)
"The
"Most
"Now
PML,"
Phytopharm
Pharmaceutical
growth
group
2002
year.
value
Hunter
Goodbody
Dublin.
question
questions
$18.90
$8,
$28.63
$38.65.
19.84%
151.5
London
Japan's